Ureter Cancer - Pipeline Review H1 2015


#283691

69pages

Global Markets Direct

$ 2000

In Stock

Ureter Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Ureter Cancer - Pipeline Review, H1 2015, provides an overview of the Ureter Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ureter Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ureter Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ureter Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ureter Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ureter Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ureter Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ureter Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ureter Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ureter Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Ureter Cancer - Overview 7
Pipeline Products for Ureter Cancer - Comparative Analysis 8
Ureter Cancer - Therapeutics under Development by Companies 9
Ureter Cancer - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Ureter Cancer - Products under Development by Companies 12
Ureter Cancer - Companies Involved in Therapeutics Development 13
Altor BioScience Corporation 13
Eli Lilly and Company 14
Exelixis, Inc. 15
Merck & Co., Inc. 16
Millennium Pharmaceuticals, Inc. 17
Ureter Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ALT-801 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
cabozantinib s-malate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
pembrolizumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ramucirumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
sapanisertib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Ureter Cancer - Recent Pipeline Updates 45
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables
Number of Products under Development for Ureter Cancer, H1 2015 7
Number of Products under Development for Ureter Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Ureter Cancer - Pipeline by Altor BioScience Corporation, H1 2015 13
Ureter Cancer - Pipeline by Eli Lilly and Company, H1 2015 14
Ureter Cancer - Pipeline by Exelixis, Inc., H1 2015 15
Ureter Cancer - Pipeline by Merck & Co., Inc., H1 2015 16
Ureter Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Ureter Cancer Therapeutics - Recent Pipeline Updates, H1 2015 45

List of Figures
Number of Products under Development for Ureter Cancer, H1 2015 7
Number of Products under Development for Ureter Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26